Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 10/20 | 0.40 |
| ▸ | CRY2 | Q49AN0 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.37 |
| ▸ | AR | P10275 | 5/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17032187 | 0.83 | ACE (0.37) | PER2ACEPIK3CDDPP4DPP8 | |
| SCHEMBL25543646 | 0.82 | CYP1A2 (0.33) | ACE | |
| SCHEMBL758907 | 0.79 | ACE (0.42) | PER2CRY2ACEPIK3CD | |
| SCHEMBL12306282 | 0.78 | PIK3CD (0.55) | PER2CRY2PIK3CDDPP4DPP8 | |
| SCHEMBL7621338 | 0.78 | ACE (0.32) | PER2ACEPIK3CDDPP4DPP8 | |
| SCHEMBL19198697 | 0.78 | PIK3CD (0.55) | PER2CRY2PIK3CDDPP4DPP8 | |
| SCHEMBL15199072 | 0.75 | PER2 (0.35) | PER2PIK3CDDPP4DPP8DPP7 | |
| SCHEMBL25541942 | 0.75 | PER2 (0.41) | PER2CRY2PIK3CDDPP4DPP8 | |
| SCHEMBL28306716 | 0.74 | ACE (0.38) | ACEDPP4DPP8DPP7 | |
| SCHEMBL19170192 | 0.74 | CYP3A4 (0.44) | PER2PIK3CDDPP4DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718618-B2 | Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230159528-A1 | VMAT2 INHIBITORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-27 | — | — | US | disclosed |
| US-8648081-B2 | Parasiticidal dihydroisoxazole compounds | ELI LILLY AND COMPANY (US) | 2014-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718618-B2 | Substituted pyrido[2,1-a]isoquinolines as VMAT2 inhibitors | SLC18A2, SLC6A2, SLC18A1 | PER2 2749/4885CRY2 4055/4885ACE 2974/4885 |
| US-20230159528-A1 | VMAT2 INHIBITORS AND METHODS OF USE | SLC18A2, SLC6A3, SLC6A2 | PER2 2661/4885CRY2 3879/4885ACE 3111/4885 |
| US-20150239879-A1 | KETONE LINKED BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | PER2 4658/4885CRY2 4849/4885ACE 140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.